The mission of JLP Health is to create a world leading company for ground-breaking discoveries of drug targets and first-in-class drugs
This enables us to develop first-in-class treatment opportunities in the areas of cancer and life-threatening diseases based on novel drug target structures.
JLP Health’s unprecedented technology is designed to explore the yet undruggable molecular universe for diseases that are a threat to human health as well as the deconvolution of the mode of action of natural compounds.
Through our unique forward genetic screening platform, we provide high-resolution information on molecular drug targets, uncover hidden efficacies and predict potential resistance mechanisms of candidate compounds. This information will be validated with unmatched reliability to set a solid fundament for innovative ‘first-in-class’ drug development projects.
By applying our cutting-edge technology with a strong team of world leading scientific experts we have the capability to deliver the next break-through drug.
Under the roof of JLP Health in Vienna, Austria, we will define novel drug target structures and explore the development of related medicines. Our ambitious goal to develop first-in-class medicines is supported by two JLP affiliate companies, Acus Laboratories GmbH and Angal Biotechnology Co., Ltd.
Acus Laboratories GmbH is a Max-Planck spin-out company based in the Max-Planck Institute for Biology of Ageing in Cologne, Germany. Equipped with unique genetic screening technology Acus offers target deconvolution services and strongly supports JLP target discovery projects.
Angal Biotechnology Co., Ltd. is based in Suzhou, China. Angal Biotechnology offers target deconvolution services through forward genetics to mainland China and fosters the development of first in-class medicines in the JLP Health family.